Daniel Arber to Prognosis
This is a "connection" page, showing publications Daniel Arber has written about Prognosis.
Connection Strength
1.540
-
Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 10 03; 160(4):365-393.
Score: 0.129
-
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
Score: 0.106
-
Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019 02 11; 20(2):15.
Score: 0.094
-
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
Score: 0.081
-
Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using high-resolution array-based comparative genomic hybridization. Am J Hematol. 2015 Aug; 90(8):E151-2.
Score: 0.072
-
The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. Int J Lab Hematol. 2015 May; 37 Suppl 1:122-32.
Score: 0.072
-
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
Score: 0.068
-
STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 2013 Nov; 27(11):2244-7.
Score: 0.063
-
The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 2013 Jan; 21(1):79-84.
Score: 0.061
-
Acute myeloid leukemia. Hematol Oncol Clin North Am. 2009 Aug; 23(4):633-54.
Score: 0.048
-
Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol. 2009 Apr; 33(4):591-8.
Score: 0.047
-
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn. 2007 Sep; 9(4):530-7.
Score: 0.042
-
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
Score: 0.034
-
Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 08 01; 109(8):2525-2532.
Score: 0.034
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.034
-
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
Score: 0.033
-
Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003 May; 119(5):672-80.
Score: 0.031
-
Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia. Hum Pathol. 2003 May; 34(5):479-83.
Score: 0.031
-
Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma. 2023 05; 64(5):972-980.
Score: 0.031
-
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
Score: 0.031
-
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol. 2023 01; 7:e2200400.
Score: 0.031
-
NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leuk Res. 2022 12; 123:106965.
Score: 0.030
-
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
Score: 0.029
-
How I investigate chronic myelomonocytic leukemia. Int J Lab Hematol. 2020 Apr; 42(2):101-108.
Score: 0.025
-
Adult precursor-B acute lymphoblastic leukemia with translocations involving chromosome band 19p13 is associated with poor prognosis. Cancer Genet Cytogenet. 1999 Feb; 109(1):58-65.
Score: 0.023
-
Hepatosplenic gamma delta T-cell lymphoma--not just alphabet soup. Adv Anat Pathol. 1998 Jan; 5(1):21-9.
Score: 0.022
-
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017 Jul 01; 148(1):49-57.
Score: 0.021
-
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017 09; 30(9):1213-1222.
Score: 0.021
-
A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. Int J Lab Hematol. 2017 Aug; 39(4):375-383.
Score: 0.021
-
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 08; 29(8):854-64.
Score: 0.019
-
Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma. Hum Pathol. 2016 09; 55:39-43.
Score: 0.019
-
Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia. 2016 Apr; 30(4):947-50.
Score: 0.018
-
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
Score: 0.017
-
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
Score: 0.017
-
Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. Adv Anat Pathol. 2013 May; 20(3):137-40.
Score: 0.016
-
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012 May; 36(5):744-52.
Score: 0.015
-
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012 Jan; 87(1):45-50.
Score: 0.014
-
Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica. 2010 Apr; 95(4):670-3.
Score: 0.012
-
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leuk Res. 2010 May; 34(5):594-7.
Score: 0.012
-
Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia. 2002 Apr; 16(4):623-31.
Score: 0.007
-
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia. 2000 Jul; 14(7):1191-6.
Score: 0.006